Phio Pharmaceuticals Corp. Operating Income Loss

• Phio Pharmaceuticals Corp. showed a decrease of -24.8% in Operating Income Loss from 2024 to 2025.
• This data is from Phio Pharmaceuticals Corp.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), Phio Pharmaceuticals Corp.'s Operating Income Loss has grown by 27.8%.
• Historical annual values: Fiscal year 2025: -$9.22 million | Fiscal year 2024: -$7.39 million | Fiscal year 2023: -$10.82 million | Fiscal year 2022: -$11.46 million | Fiscal year 2021: -$13.51 million | Fiscal year 2020: -$8.79 million | Fiscal year 2019: -$8.99 million | Fiscal year 2018: -$7.36 million | Fiscal year 2017: -$14.06 million | Fiscal year 2016: -$9.02 million | Fiscal year 2015: -$10.24 million | Fiscal year 2014: -$8.83 million | Fiscal year 2013: -$20.95 million | Fiscal year 2012: -$12.98 million | Fiscal year 2011: -$12.77 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026